Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
出版年份 2013 全文链接
标题
Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
作者
关键词
Tofacitinib, Rheumatoid arthritis, Treatment outcome, Meta-analysis
出版物
BMC MUSCULOSKELETAL DISORDERS
Volume 14, Issue 1, Pages -
出版商
Springer Nature
发表日期
2013-10-18
DOI
10.1186/1471-2474-14-298
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors
- (2012) Anna Yarilina et al. ARTHRITIS AND RHEUMATISM
- Kinase Inhibition — A New Approach to the Treatment of Rheumatoid Arthritis
- (2012) David A. Fox NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Strategies for the Management of Rheumatoid Arthritis
- (2012) W.S. Wilkie et al. ORTHOPEDICS
- Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis
- (2012) Kalle J. Aaltonen et al. PLoS One
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
- (2012) Jasvinder A. Singh et al. ARTHRITIS CARE & RESEARCH
- Kinase inhibitors: a new class of antirheumatic drugs
- (2012) Vasileios Kyttaris Drug Design Development and Therapy
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- (2011) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
- (2011) Roy Fleischmann et al. ARTHRITIS AND RHEUMATISM
- Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
- (2011) Yoshiya Tanaka et al. ARTHRITIS CARE & RESEARCH
- Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study
- (2010) Tim Bongartz et al. ARTHRITIS AND RHEUMATISM
- Cutaneous nodules in patients with rheumatoid arthritis: a case report and review of literatures
- (2010) Tadashi Nakamura et al. CLINICAL RHEUMATOLOGY
- A Supratherapeutic Dose of the Janus Kinase Inhibitor Tasocitinib (CP-690,550) Does Not Prolong QTc Interval in Healthy Participants
- (2010) Sriram Krishnaswami et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
- (2009) J H Coombs et al. ANNALS OF THE RHEUMATIC DISEASES
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started